Immedica Pharma
As of the edition of 20 October 2026, Immedica Pharma runs 6 drugs, 6 of them marketed; it is on route A at 0 targets and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 3 company names in this family.
- Marinus Pharmaceuticals: acquired in 2025; successor Immedica Pharma AB
Drugs by status
| Status | Count |
|---|---|
| Marketed | 6 |
| Total | 6 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Hydrocortisone | none listed | 5 |
| Phenylbutanoic acid | none listed | 0 |
| Ganaxolone | Ends 2029 (exclusivity) | 0 |
| Glycerol phenylbutyrate | none listed | 0 |
| Pegzilarginase | Ends 2038 (computed from the first US licence) | 0 |
| Emedastine | none listed | 2 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 1 target.
| Target | Route |
|---|---|
| HRH1 Histamine H1 receptor | Route B |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Immedica Pharma needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Nervous system: 20 trials led
- Inherited and neonatal: 6 trials led
- Cancer: 4 trials led